Data sourcesSEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company
EBSEmergent BioSolutions Inc.
CIK 0001367644
Disclosed transactions27
Buys / sells0 / 0
Max Insider Score23
Connections11with evidence
EBS · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Tax withholding | F | $16K 2,018 sh | Jun 8, 2026 | Jun 10, 2026 traded Jun 8, 2026 | +2d | SEC FORM 4 | |
|
9
WAWilliams Paul AnthonySVP, Products Business |
EBSEmergent BioSolutions Inc. Tax withholding |
| Jun 10, 2026 traded Jun 8, 2026 |
| 9 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Tax withholding | F | $14K 1,741 sh | Jun 8, 2026 | Jun 10, 2026 traded Jun 8, 2026 | +2d | SEC FORM 4 | |
| 21 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Grant or award | A | — 100.1K sh | Apr 29, 2026 | May 1, 2026 traded Apr 29, 2026 | +2d | SEC FORM 4 | |
| 21 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Grant or award | A | — 100.1K sh | Apr 29, 2026 | May 1, 2026 traded Apr 29, 2026 | +2d | SEC FORM 4 | |
| 21 | PJPerl JessicaSVP, General Counsel, Corp Sec | EBSEmergent BioSolutions Inc. Grant or award | A | — 104.3K sh | Apr 29, 2026 | May 1, 2026 traded Apr 29, 2026 | +2d | SEC FORM 4 | |
| 21 | LCLowry Simon CSVP, R&D, CMO | EBSEmergent BioSolutions Inc. Grant or award | A | — 100.1K sh | Apr 29, 2026 | May 1, 2026 traded Apr 29, 2026 | +2d | SEC FORM 4 | |
| 21 | WAWilliams Paul AnthonySVP, Products Business | EBSEmergent BioSolutions Inc. Grant or award | A | — 100.1K sh | Apr 29, 2026 | May 1, 2026 traded Apr 29, 2026 | +2d | SEC FORM 4 | |
| 16 | LCLowry Simon CSVP, R&D, CMO | EBSEmergent BioSolutions Inc. Tax withholding | F | $90K 10.6K sh | Mar 5, 2026 | Mar 5, 2026 traded Mar 5, 2026 | +0d | SEC FORM 4 | |
| 17 | LCLowry Simon CSVP, R&D, CMO | EBSEmergent BioSolutions Inc. Grant or award | A | — 44.8K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC FORM 4 | |
| 17 | PJPerl JessicaSVP, General Counsel, Corp Sec | EBSEmergent BioSolutions Inc. Grant or award | A | — 46.7K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC FORM 4 | |
| 16 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Tax withholding | F | $80K 9,493 sh | Mar 5, 2026 | Mar 5, 2026 traded Mar 5, 2026 | +0d | SEC FORM 4 | |
| 17 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Grant or award | A | — 44.8K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC FORM 4 | |
| 16 | WAWilliams Paul AnthonySVP, Products Business | EBSEmergent BioSolutions Inc. Tax withholding | F | $79K 9,397 sh | Mar 5, 2026 | Mar 5, 2026 traded Mar 5, 2026 | +0d | SEC FORM 4 | |
| 17 | WAWilliams Paul AnthonySVP, Products Business | EBSEmergent BioSolutions Inc. Grant or award | A | — 44.8K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC FORM 4 | |
| 16 | PJPerl JessicaSVP, General Counsel, Corp Sec | EBSEmergent BioSolutions Inc. Tax withholding | F | $55K 6,465 sh | Mar 5, 2026 | Mar 5, 2026 traded Mar 5, 2026 | +0d | SEC FORM 4 | |
| 13 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Grant or award | A | — 44.8K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC FORM 4 | |
| 16 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Tax withholding | F | $69K 8,199 sh | Mar 5, 2026 | Mar 5, 2026 traded Mar 5, 2026 | +0d | SEC FORM 4 | |
| 9 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Tax withholding | F | $6,880 630 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 16 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Disposition to issuer | D | $63K 5,771 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 16 | WAWilliams Paul AnthonySVP, Products Business | EBSEmergent BioSolutions Inc. Disposition to issuer | D | $95K 8,655 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 9 | WAWilliams Paul AnthonySVP, Products Business | EBSEmergent BioSolutions Inc. Tax withholding | F | $11K 1,022 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 23 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Disposition to issuer | D | $315K 28.8K sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 9 | GCGlessner ColeenEVP, Quality & Ethics, and CPL | EBSEmergent BioSolutions Inc. Tax withholding | F | $31K 2,852 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC FORM 4 | |
| 9 | PJPerl JessicaSVP, General Counsel, Corp Sec | EBSEmergent BioSolutions Inc. Tax withholding | F | $10K 918 sh | Feb 9, 2026 | Feb 10, 2026 traded Feb 9, 2026 | +1d | SEC FORM 4 | |
| 9 | LCLowry Simon CSVP, R&D, CMO | EBSEmergent BioSolutions Inc. Tax withholding | F | $40K 3,543 sh | Dec 14, 2025 | Dec 16, 2025 traded Dec 14, 2025 | +2d | SEC FORM 4 | |
| 9 | HWHartzel WilliamSVP, Bioservices | EBSEmergent BioSolutions Inc. Tax withholding | F | $6,637 610 sh | Nov 11, 2025 | Nov 13, 2025 traded Nov 11, 2025 | +2d | SEC FORM 4 | |
LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
CGCN GROUP, LLCLDA Q2 2026 second quarter · DIS, Health issues, Homeland security, Budget/appropriations · Aug 26, 2026